University of Arkansas
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Arkansas sits in the top decile of US sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count).
University of Arkansas: 318 sponsored US clinical trials, 37 recruiting.
University of Arkansas sponsors 318 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 202 completed. 17 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 15 trials.
Top-decile sponsor footprint
University of Arkansas ranks in the top decile of sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
202 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
318 total, page 6 of 7
Safety and Tolerability of Modafinil for Methamphetamine Dependence
NCT00569374
Thyroid Disease Serum Repository
NCT00592605
Telemedicine-Based Collaborative Care to Reduce Rural Disparities
NCT00439452
Disulfiram for Cocaine Abuse
NCT00395850
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
NCT00577512
Study With Candida Antigen for Treatment of Warts
NCT00569231
Combined Effects of Nutritional and Exercise Countermeasures
NCT00447044
Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients
NCT00446888
Treatment of Oral Premalignant Lesions With 5-ALA PDT
NCT00571974
Analyzing the Composition of Tears to Identify Cancer
NCT00574678
Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging
NCT00592982
Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery
NCT00393848
Drug Discrimination in Methadone-Maintained Humans Study 1
NCT00593463
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
NCT00570258
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
NCT00653263
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
NCT00573391
Use of Modafinil in the Treatment of Tinnitus
NCT00591019
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
NCT00574080
Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus
NCT00329524
Near-Continuous, Noninvasive Blood Pressure Monitoring to Improve Outcomes in Pediatric Transport
NCT00279591
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
NCT00128921
Head and Neck Cancer Screening and Serum Repository
NCT00592371
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00287222
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma
NCT01622582
Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans
NCT00654953
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
NCT00203502
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
NCT00569868
Thyroid Dysfunction in Head and Neck Surgery Patients
NCT00592514
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
NCT00577902
Real-Time Internet Evaluation of Swallowing
NCT00580138
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
NCT00111748
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
NCT00571987
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
NCT00090493
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
NCT00113919
Effect of Thiazolidinedione Treatment Vascular Risk Markers
NCT00571506
Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
NCT00575029
UARK 2003-33, Total Therapy III
NCT00081939
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
NCT00093028
Glucocorticoids Promote Osteoclast Survival
NCT00572299
UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma
NCT00113932
Palliative Strategies in Spinal Cord Injury (SCI)
NCT00594178
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
NCT00089453
Treatment of Language and Memory in Patients With Alzheimer's Disease
NCT00593372
Therapeutic Research in Multiple Myeloma
NCT00572338
Treatment of Dysphagia Using the Mendelsohn Maneuver
NCT00592761
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients
NCT00107614
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
NCT00580372
Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins
NCT00593424
Percutaneous Removal and Margin Ablation for Breast Cancer
NCT00574301
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
NCT00083460
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 40 |
| Phase 2 | 62 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the University of Arkansas pipeline
37 recruiting of 318 indexed (12% open); 202 completed (64%).
Phase mix: 17 late (III/IV) vs 102 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Arkansas: open-pipeline peers nationwide
Peers matched on 318 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 318 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
- Allergan · 314 trials · 0% recruiting
- Celgene · 308 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Jazz Pharmaceuticals · 12% recruiting · 128 trials
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
Related
What to do with this University of Arkansas page
318 registered trials is a research-attention snapshot, not an endorsement of University of Arkansas or any single study.
- 37 of University of Arkansas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition University of Arkansas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Arkansas pipeline card: 318 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.